AGENUS INC Net Cash Provided by (Used in) Investing Activities, Continuing Operations
AGENUS INC (AGEN) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$1.49 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-10
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was -$1.49M.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $4.25M, a 60.21% decline year-over-year.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $9.04M, a 63.82% decline year-over-year.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$5.96M, a 132.39% decline year-over-year.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $2.06M, a 88.27% decline from fiscal 2016.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was $17.60M.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$31.23M.
- AGENUS INC net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was -$16.81M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|
| 2018-03-31 | -$1.49M 10-Q · filed 2018-05-10 | $2.76M derived: sum of 2 quarters · filed 2018-05-10 | $11.80M derived: sum of 3 quarters · filed 2018-05-10 | $5.84M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-12-31 | $4.25M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $13.29M derived: sum of 2 quarters · filed 2018-03-16 | $7.33M derived: sum of 3 quarters · filed 2018-03-16 | $2.06M 10-K · filed 2018-03-16 |
| 2017-09-30 | $9.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $3.08M derived: sum of 2 quarters · filed 2017-11-07 | -$2.18M 10-Q · filed 2017-11-07 | $8.49M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-06-30 | -$5.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$11.22M 10-Q · filed 2017-08-07 | -$550.20K derived: sum of 3 quarters · filed 2018-05-10 | $24.43M derived: sum of 4 quarters · filed 2018-05-10 |
| 2017-03-31 | -$5.26M 10-Q · filed 2018-05-10 | $5.41M derived: sum of 2 quarters · filed 2018-05-10 | $30.39M derived: sum of 3 quarters · filed 2018-05-10 | $48.79M derived: sum of 4 quarters · filed 2018-05-10 |
| 2016-12-31 | $10.67M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | $35.66M derived: sum of 2 quarters · filed 2018-03-16 | $54.06M derived: sum of 3 quarters · filed 2018-03-16 | $17.60M 10-K · filed 2018-03-16 |
| 2016-09-30 | $24.98M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $43.38M derived: sum of 2 quarters · filed 2017-11-07 | $6.92M 10-Q · filed 2017-11-07 | -$21.02M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-06-30 | $18.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | -$18.06M 10-Q · filed 2017-08-07 | -$46.00M derived: sum of 3 quarters · filed 2018-03-16 | -$47.30M derived: sum of 4 quarters · filed 2018-03-16 |
| 2016-03-31 | -$36.46M 10-Q · filed 2017-05-04 | -$64.40M derived: sum of 2 quarters · filed 2018-03-16 | -$65.71M derived: sum of 3 quarters · filed 2018-03-16 | -$81.90M derived: sum of 4 quarters · filed 2018-03-16 |
| 2015-12-31 | -$27.94M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-16 | -$29.25M derived: sum of 2 quarters · filed 2018-03-16 | -$45.44M derived: sum of 3 quarters · filed 2018-03-16 | -$31.23M 10-K · filed 2018-03-16 |
| 2015-09-30 | -$1.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | -$17.50M derived: sum of 2 quarters · filed 2016-11-09 | -$3.29M 10-Q · filed 2016-11-09 | -$5.00M derived: sum of 4 quarters · filed 2017-03-16 |
| 2015-06-30 | -$16.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | -$1.99M 10-Q · filed 2016-08-04 | -$3.69M derived: sum of 3 quarters · filed 2017-03-16 | |
| 2015-03-31 | $14.21M 10-Q · filed 2016-05-09 | $12.51M derived: sum of 2 quarters · filed 2017-03-16 | ||
| 2014-12-31 | -$1.70M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-16 | -$16.81M 10-K · filed 2017-03-16 | ||
| 2014-09-30 | -$15.11M 10-Q · filed 2015-11-04 | |||
| 2013-12-31 | -$363.52K 10-K · filed 2016-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |